BioNxt Solutions (TSE:BNXT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioNxt Solutions Inc. has entered into a master services agreement with a German international contract research, development, and manufacturing organization to propel product development, focusing on their oral dissolvable drug formulations for the multiple sclerosis market. The partnership aims to streamline BioNxt’s path towards clinical studies and commercialization of their proprietary Cladribine dosage form, tapping into a market poised to grow significantly by 2033.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.